Márk Barok
Impact in
- Oncology top 2%
- HER2/EGFR in Cancer Research
- Peptidase Inhibition and Analysis
- CAR-T cell therapy research
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
-
- Monoclonal and Polyclonal Antibodies Research
Papers in
- Oncology 18
- HER2/EGFR in Cancer Research 16
- Peptidase Inhibition and Analysis 3
- Cancer Cells and Metastasis 2
-
- Monoclonal and Polyclonal Antibodies Research 17
- Co-authors
- Jorma Isola (14 shared papers)Heikki Joensuu (11 shared papers)Minna Tanner (5 shared papers)János Szöllõsi (6 shared papers)György Vereb (7 shared papers)Péter Nagy (4 shared papers)Maija Puhka (3 shared papers)István Juhász (2 shared papers)
In The Last Decade
Márk Barok
20 papers receiving 1.6k citations
Márk Barok's Hit Papers
Peers
Comparison fields: 5 of 73
- Oncology 1.2k
- Radiology, Nuclear Medicine and Imaging 838
- Immunology and Allergy 140
- Cancer Research 184
- Genetics 110
Countries citing papers authored by Márk Barok
This map shows the geographic impact of Márk Barok's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Márk Barok with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Márk Barok more than expected).
Fields of papers citing papers by Márk Barok
This network shows the impact of papers produced by Márk Barok. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Márk Barok. The network helps show where Márk Barok may publish in the future.
Co-authors
The 25 scholars most cited alongside Márk Barok, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 22 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab emtansine: mechanisms of action and drug resistance Hit paper breakdown → | 2014 | 426 |
| 2 | 2007 | 180 | |
| 3 | 2011 | 173 | |
| 4 | 2011 | 124 | |
| 5 | 2007 | 117 | |
| 6 | 2010 | 90 | |
| 7 | 2019 | 71 | |
| 8 | 2018 | 71 | |
| 9 | 2007 | 70 | |
| 10 | 2008 | 70 | |
| 11 | 2020 | 64 | |
| 12 | 2008 | 53 | |
| 13 | 2007 | 38 | |
| 14 | 2021 | 31 | |
| 15 | 2008 | 30 | |
| 16 | 2024 | 11 | |
| 17 | 2023 | 7 | |
| 18 | 2016 | 4 | |
| 19 | 2025 | 2 | |
| 20 | 2025 | 1 |
About Márk Barok
Márk Barok is a scholar working on Oncology, Radiology, Nuclear Medicine and Imaging, Molecular Biology, Immunology and Allergy and Cell Biology, having authored 22 papers that have together received 1.6k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (17 papers), HER2/EGFR in Cancer Research (16 papers), Cell Adhesion Molecules Research (6 papers), Peptidase Inhibition and Analysis (3 papers), Cancer Genomics and Diagnostics (2 papers), Cancer Cells and Metastasis (2 papers), Extracellular vesicles in disease (2 papers) and Glycosylation and Glycoproteins Research (2 papers). The work is most often cited by research in Oncology (1.2k citations), Radiology, Nuclear Medicine and Imaging (838 citations), Immunology and Allergy (140 citations), Cancer Research (184 citations) and Genetics (110 citations). Márk Barok has collaborated with scholars based in Finland, Hungary and Canada. Frequent co-authors include Jorma Isola, Heikki Joensuu, Minna Tanner, János Szöllõsi, György Vereb, Péter Nagy, Maija Puhka, István Juhász, Pirjo Laakkonen and Markku Tammi. Their work appears in journals such as Cancer Letters, Molecular Cancer Therapeutics, Breast Cancer Research, Clinical & Experimental Metastasis and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.